Mizuho Medy (4595) Fundamentals 2026 — P/E 9.8x, Revenue Analysis | SniperIQ
Mizuho Medy (4595) is a JP-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ¥31.8B, trading at ¥1668.00 on the JPX. This SniperIQ fundamentals page covers Mizuho Medy's valuation (P/E 9.8x, P/B 1.7x), profitability (net margin 30.0%), revenue (¥11.3B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Mizuho Medy's market cap?
Mizuho Medy (4595) has a market capitalization of approximately ¥31.8B, trading at ¥1668.00 on the JPX. Market cap moves with the live share price.
What is Mizuho Medy's P/E ratio?
Mizuho Medy's trailing twelve-month P/E ratio is 9.8x, with a price-to-book (P/B) of 1.7x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Mizuho Medy?
Mizuho Medy runs a net profit margin of 30.0%, a gross margin of 68.6%, and an operating margin of 39.6%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Mizuho Medy generate?
Mizuho Medy reported revenue of ¥11.3B for fiscal year 2025, with net income of ¥3.4B and earnings per share (EPS) of 179.8. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Mizuho Medy pay a dividend?
Mizuho Medy offers a trailing dividend yield of about 6.0%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Mizuho Medy financially healthy?
Mizuho Medy carries a debt-to-equity ratio of 0.00x and a current ratio of 11.59x, with a market beta of 0.52. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Mizuho Medy a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Mizuho Medy (4595) the key facts are: market cap ¥31.8B, P/E 9.8x, revenue ¥11.3B, 52-week range 1410-1930. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Mizuho Medy's full fundamentals live
Get Mizuho Medy's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.